Madrigal Pharmaceuticals (MDGL) Gains from Sales and Divestitures (2012 - 2018)
Madrigal Pharmaceuticals (MDGL) reported Gains from Sales and Divestitures of $52064.0 for Q4 2018, down 2.02% year-over-year from $53135.0 in Q4 2017, and little changed quarter-over-quarter from $52064.0 in Q3 2018.
Madrigal Pharmaceuticals (MDGL) Gains from Sales and Divestitures (2012 - 2018) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 7 years of Gains from Sales and Divestitures data on file, last reported at $52064.0 in Q4 2018.
- Gains from Sales and Divestitures for Q4 2018 came in at $52064.0, down 2.02% year-over-year; the trailing twelve-month figure through Dec 2018 was $52064.0 (down 2.02% YoY), and the FY2018 annual result was $52064.0, down 2.02% from the prior year.
- Gains from Sales and Divestitures steadied at $52064.0 in Q4 2018 per MDGL's latest filing, from $52064.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $71211.0 in Q4 2015 and troughed at $9756.0 in Q1 2015.
- A 5-year average of $42048.1 and a median of $48712.0 in 2015 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2014 and 2016: Gains from Sales and Divestitures decreased 28.33% in 2014, then surged 256.47% in 2016.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $39508.0 in 2014, then soared by 80.24% to $71211.0 in 2015, then declined by 25.38% to $53135.0 in 2016, then changed by 0.0% to $53135.0 in 2017, then dropped by 2.02% to $52064.0 in 2018.
- Business Quant data shows MDGL's Gains from Sales and Divestitures at $52064.0 in Q4 2018, $52064.0 in Q3 2018, and $53135.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 52,064.00 |
| Dec 31, 2018 | 52,064.00 |
| Sep 30, 2018 | 52,064.00 |
| Sep 30, 2018 | 52,064.00 |
| Dec 31, 2017 | 53,135.00 |
| Dec 31, 2017 | 53,135.00 |
| Sep 30, 2017 | 52,063.00 |
| Sep 30, 2017 | 52,063.00 |
| Dec 31, 2016 | 53,135.00 |
| Dec 31, 2016 | 53,135.00 |
| Sep 30, 2016 | 62,574.00 |
| Sep 30, 2016 | 62,574.00 |
| Jun 30, 2016 | 67,858.00 |
| Jun 30, 2016 | 67,858.00 |
| Mar 31, 2016 | 34,777.00 |
| Mar 31, 2016 | 34,777.00 |
| Dec 31, 2015 | 71,211.00 |
| Dec 31, 2015 | 71,211.00 |
| Sep 30, 2015 | 45,361.00 |
| Sep 30, 2015 | 45,361.00 |